title: Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort.
abstract: The demographics and clinical features were compared between those with (29.4%) and without concurrent substance use disorder (SUD) in 2541 outpatients with major depression (MDD) enrolled in the Sequenced Treatment Alternatives to Relieve Depression study. Compared to those without SUD, MDD patients with concurrent SUD were more likely to be younger, male, divorced or never married, and at greater current suicide risk, and have an earlier age of onset of depression, greater depressive symptomatology, more previous suicide attempts, more frequent concurrent anxiety disorders, and greater functional impairment (p = 0.048 to <0.0001). They were also less likely to be Hispanic and endorse general medical comorbidities (p = 0.006 and 0.002, respectively).
authors.affiliation: VA Medical Center, Tuscaloosa, AL 35404, USA. lori.davis@med.va.gov
authors.forename: Lori L
authors.initials: LL
authors.lastname: Davis
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Frazier
authors.forename: Mustafa M
authors.initials: MM
authors.lastname: Husain
authors.forename: Diane
authors.initials: D
authors.lastname: Warden
authors.forename: Madhukar
authors.initials: M
authors.lastname: Trivedi
authors.forename: Maurizio
authors.initials: M
authors.lastname: Fava
authors.forename: Paolo
authors.initials: P
authors.lastname: Cassano
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: McGrath
authors.forename: G K
authors.initials: GK
authors.lastname: Balasubramani
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Wisniewski
authors.forename: A John
authors.initials: AJ
authors.lastname: Rush
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology / Q000534:rehabilitation; D016642:Bupropion / Q000627:therapeutic use; D015283:Citalopram / Q000627:therapeutic use; D015928:Cognitive Behavioral Therapy; D015331:Cohort Studies; D003131:Combined Modality Therapy; D015897:Comorbidity; D003511:Cyclohexanols / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000453:epidemiology* / Q000523:psychology / Q000534:rehabilitation; D017831:Diagnosis, Dual (Psychiatry); D005163:Factor Analysis, Statistical; D005260:Female; D006801:Humans; D008297:Male; D010555:Personality Inventory; D019233:Retreatment; D012307:Risk Factors; D020280:Sertraline / Q000627:therapeutic use; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000523:psychology / Q000534:rehabilitation; D013405:Suicide / Q000523:psychology; D000069470:Venlafaxine Hydrochloride; D000092864:Suicide Prevention
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D016642:Bupropion; D015283:Citalopram; D000069470:Venlafaxine Hydrochloride; D020280:Sertraline